Form 3 Ioannidou Sofia

Initial statement of beneficial ownership of securities

Published: 2018-10-18 20:18:29
Submitted: 2018-10-18
Period Ending In: 2018-10-18
doc3.html FORM 3 SUBMISSION


>

SEC FORM 3

SEC Form 3
FORM 3 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0104
Estimated average burden
hours per response: 0.5
1. Name and Address of Reporting Person*
Ioannidou Sofia

(Last) (First) (Middle)
C/O LOGICBIO THERAPEUTICS, INC.
610 MAIN ST., 3RD FLOOR

(Street)
CAMBRIDGE MA 02139

(City) (State) (Zip)
2. Date of Event Requiring Statement (Month/Day/Year)
10/18/2018
3. Issuer Name and Ticker or Trading Symbol
LogicBio Therapeutics, Inc. [ LOGC ]
4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
X Director 10% Owner
Officer (give title below) Other (specify below)
5. If Amendment, Date of Original Filed (Month/Day/Year)
6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4) 2. Amount of Securities Beneficially Owned (Instr. 4) 3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) 4. Nature of Indirect Beneficial Ownership (Instr. 5)
Table II - Derivative Securities Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4) 2. Date Exercisable and Expiration Date (Month/Day/Year) 3. Title and Amount of Securities Underlying Derivative Security (Instr. 4) 4. Conversion or Exercise Price of Derivative Security 5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) 6. Nature of Indirect Beneficial Ownership (Instr. 5)
Date Exercisable Expiration Date Title Amount or Number of Shares
Series B Convertible Preferred Stock (1) (1) Common Stock 1,367,413 (1) I See Footnote(2)
Explanation of Responses:
1. Series B Convertible Preferred Stock is convertible into shares of common stock at any time at the holder's election and automatically upon the consummation of a qualified public offering of the registrant. There is no expiration date for the Series B Convertible Preferred Stock.
2. The Reporting Person is a director of Andera Partners, the company managing BioDiscovery 5. BioDiscovery 5 is the direct beneficial owner of these securities. The Reporting Person disclaims beneficial ownership, within the meaning of Section 16 of the Securities Exchange Act of 1934, as amended, or otherwise of such portion of these securities in which the Reporting Person has no pecuniary interest.
Remarks:
Exhibit List Exhibit 24 - Power of Attorney
/s/ Matthias Jaffe, as Attorney-In-Fact 10/18/2018
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
1
doc3.xml FORM 3 SUBMISSION
Schema Version:
X0206
Document Type:
3
Period Of Report:
2018-10-18
No Securities Owned:
0

Issuer

Issuer Cik
0001664106
Issuer Name
LogicBio Therapeutics, Inc.
Issuer Trading Symbol
LOGC

Reporting Owner

Reporting Owner Id

Rpt Owner Cik
0001752486
Rpt Owner Name
Ioannidou Sofia

Reporting Owner Address

Rpt Owner Street1
C/O LOGICBIO THERAPEUTICS, INC.
Rpt Owner Street2
610 MAIN ST., 3RD FLOOR
Rpt Owner City
CAMBRIDGE
Rpt Owner State
MA
Rpt Owner Zip Code
02139

Reporting Owner Relationship

Is Director
1
Is Officer
0
Is Ten Percent Owner
0
Is Other
0

Derivative Holding

Security Title
Series B Convertible Preferred Stock
@attributes Id
F1
@attributes Id
F1
@attributes Id
F1

Underlying Security

Underlying Security Title
Common Stock
Underlying Security Shares
1367413

Ownership Nature

Direct Or Indirect Ownership
I

Nature Of Ownership

Value
See Footnote
@attributes Id
F2

Footnote

0
Series B Convertible Preferred Stock is convertible into shares of common stock at any time at the holder's election and automatically upon the consummation of a qualified public offering of the registrant. There is no expiration date for the Series B Convertible Preferred Stock.
1
The Reporting Person is a director of Andera Partners, the company managing BioDiscovery 5. BioDiscovery 5 is the direct beneficial owner of these securities. The Reporting Person disclaims beneficial ownership, within the meaning of Section 16 of the Securities Exchange Act of 1934, as amended, or otherwise of such portion of these securities in which the Reporting Person has no pecuniary interest.
Remarks:
Exhibit List Exhibit 24 - Power of Attorney

Owner Signature

Signature Name
/s/ Matthias Jaffe, as Attorney-In-Fact
Signature Date
2018-10-18
attachment1.htm EX-24 DOCUMENT


> ENT> EX-24 2 attachment1.htm EX-24 DOCUMENT
                               LIMITED POWER OF ATTORNEY

        The undersigned hereby constitutes and appoints Matthias Jaffe with full
power of substitution, as the undersigned's true and lawful attorney-in-fact to:

       (1)  prepare, execute in the undersigned's name and on the undersigned's
            behalf, and submit to the U.S. Securities and Exchange Commission
            (the "SEC") a Form ID, including amendments thereto, and any other
            documents necessary or appropriate to obtain codes and passwords
            enabling the undersigned to make electronic filings with the SEC of
            reports required by Section 16(a) of the Securities Exchange Act of
            1934, as amended, or any rule or regulation of the SEC;

       (2)  execute for and on behalf of the undersigned, in the undersigned's
            capacity as officer and/or director of LogicBio Therapeutics, Inc.
            (the "Company"), Forms 3, 4, 5 and any Schedules 13D or 13G in
            accordance with Section 16(a) of the Securities Exchange Act of
            1934, as amended, and the rules thereunder;

       (3)  do and perform any and all acts for and on behalf of the
            undersigned that may be necessary or desirable to complete and
            execute any such Form 3, 4, or 5 or Schedule 13D or 13G, complete
            and execute any amendment or amendments thereto, and timely file
            such form with the SEC and any stock exchange or similar authority;
            and

       (4)  take any other action of any type whatsoever in connection with the
            foregoing that, in the opinion of such attorney-in-fact, may be of
            benefit to, in the best interest of, or legally required by, the
            undersigned, it being understood that the documents executed by such
            attorney-in-fact on behalf of the undersigned pursuant to this Power
            of Attorney shall be in such form and shall contain such terms and
            conditions as such attorney-in-fact may approve in such
            attorney-in-fact's discretion.

        The undersigned hereby grants to such attorney-in-fact full power and
authority to do and perform any and every act and thing whatsoever requisite,
necessary, or proper to be done in the exercise of any of the rights and powers
herein granted, as fully to all intents and purposes as the undersigned might or
could do if personally present, with full power of substitution or revocation,
hereby ratifying and confirming all that such attorney-in-fact, or such
attorney-in-fact's substitute or substitutes, shall lawfully do or cause to be
done by virtue of this power of attorney and the rights and powers herein
granted.  The undersigned acknowledges that the foregoing attorneys-in-fact, in
serving in such capacity at the request of the undersigned, are not assuming,
nor is the Company assuming, any of the undersigned's responsibilities to comply
with Section 16 of the Securities Exchange Act of 1934, as amended.

        This Power of Attorney shall remain in full force and effect until the
undersigned is no longer required to file Forms 3, 4, 5, and any Schedules 13D
or 13G with respect to the undersigned's holdings of and transactions in
securities issued by the Company, unless earlier revoked by the undersigned in a
signed writing delivered to the foregoing attorney-in-fact.

        IN WITNESS WHEREOF, the undersigned has caused this Power of Attorney to
be executed as of this 18th day of September, 2018.

                                        /s/ Sofia Ioannidou
                                        -------------------------
                                        Sofia Ioannidou

Additional Files
FileSequenceDescriptionTypeSize
0000899243-18-027012.txt   Complete submission text file   8797
$LOGC

© 2019 SEC.report
SEC CFR Title 17 of the Code of Federal Regulations.